We Give Shareholders a Voice

Forty Seven, Inc. Loss Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Forty Seven, Inc. (“Forty Seven” or the “Company”) (NASDAQ: FTSV) to Gilead Sciences, Inc. (“Gilead”) (NASDAQ: GILD). Under the terms of the merger, Gilead will acquire Forty Seven for $95.50 per share in cash.

The Forty Seven merger investigation concerns whether the Board of Forty Seven breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Gilead is underpaying for Forty Seven shares, thus unlawfully harming Forty Seven shareholders.

To receive more information, please fill out the form.

Enter Your Details Below

This submission does not create an attorney-client relationship. We will keep you up to date with this investigation, and should this investigation evolve, we will contact you to discuss whether to establish an attorney client relationship at no cost to you.

Review our Privacy Policy